Overview

SNS-301 Monotherapy in High Risk MDS and CMML

Status:
Withdrawn
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 in patients with ASPH+ high risk MDS and CMML.
Phase:
Phase 2
Details
Lead Sponsor:
Sensei Biotherapeutics, Inc.